0
Signin
countryflagUS

18889881171

AAPL 220.84 -2.9189% MSFT 380.45 0.0763% NVDA 108.76 1.6639% GOOGL 164.04 -1.1033% GOOG 165.98 -1.0905% AMZN 196.59 1.0538% META 605.71 1.291% AVGO 190.09 3.0577% LLY 824.06 -0.6869% TSLA 230.58 3.7947% TSM 170.97 0.1875% V 332.14 -2.7352% JPM 229.14 -1.3263% UNH 486.04 1.2119% NVO 78.11 -1.064% WMT 87.44 -0.4327% LVMUY 136.76 0.4407% XOM 109.16 -2.3614% LVMHF 687.83 1.0029% MA 525.8 -2.1075%
AAPL 220.84 -2.9189% MSFT 380.45 0.0763% NVDA 108.76 1.6639% GOOGL 164.04 -1.1033% GOOG 165.98 -1.0905% AMZN 196.59 1.0538% META 605.71 1.291% AVGO 190.09 3.0577% LLY 824.06 -0.6869% TSLA 230.58 3.7947% TSM 170.97 0.1875% V 332.14 -2.7352% JPM 229.14 -1.3263% UNH 486.04 1.2119% NVO 78.11 -1.064% WMT 87.44 -0.4327% LVMUY 136.76 0.4407% XOM 109.16 -2.3614% LVMHF 687.83 1.0029% MA 525.8 -2.1075%

Fresenius SE & Co KGaA ADR

Healthcare US FSNUY

10.54USD
-0.16(1.50%)

Last update at 2025-03-11T19:50:00Z

Day Range

10.5010.58
LowHigh

52 Week Range

5.878.38
LowHigh

Fundamentals

  • Previous Close 10.70
  • Market Cap17531.15M
  • Volume361
  • P/E Ratio16.87
  • Dividend Yield3.21%
  • EBITDA4683.00M
  • Revenue TTM41599.00M
  • Revenue Per Share TTM18.46
  • Gross Profit TTM 10725.00M
  • Diluted EPS TTM0.45

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-310M5000M10000M15000M20000M25000M30000M35000M40000M
Total Revenue
Net Income

Balancesheet

2018-12-312019-12-312020-12-312021-12-312022-12-310M10000M20000M30000M40000M50000M60000M70000M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-1000M-800M-600M-400M-200M0M200M400M600M800M1000M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-313600M3800M4000M4200M4400M4600M4800M5000M5200M5400M5600M5800M6000M6200M6400M6600M

Dividends Paid

2018-12-312019-12-312020-12-312021-12-312022-12-310M100M200M300M400M500M600M700M800M900M1000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 2814.00M 3652.00M 3726.00M 3912.00M 4664.00M
Minority interest -745.00000M -1001.00000M 9074.00M 9802.00M 9597.00M
Net income 2117.00M 2819.00M 2823.00M 3029.00M 2027.00M
Selling general administrative 5524.00M 4394.00M 4373.00M 4386.00M 3857.00M
Selling and marketing expenses 1220.00M 1059.00M 1057.00M 1020.00M 1016.00M
Gross profit 10725.00M 10311.00M 10316.00M 10348.00M 9834.00M
Reconciled depreciation 2973.00M 2667.00M 2715.00M 2452.00M 1430.00M
Ebit 3508.00M 4158.00M 4385.00M 4631.00M 4797.00M
Ebitda 6481.00M 6949.00M 7162.00M 7216.00M 6227.00M
Depreciation and amortization 2973.00M 2791.00M 2777.00M 2585.00M 1430.00M
Non operating income net other - - - - 0.00000M
Operating income 3508.00M 4158.00M 4385.00M 4631.00M 5251.00M
Other operating expenses 37519.00M 33362.00M 31923.00M 30807.00M 29088.00M
Interest expense 694.00M 630.00M 752.00M 881.00M 942.00M
Tax provision 697.00M 833.00M 903.00M 883.00M 950.00M
Interest income 187.00M 124.00M 93.00M 162.00M 355.00M
Net interest income -507.00000M -506.00000M -659.00000M -719.00000M -587.00000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 697.00M 833.00M 903.00M 883.00M 950.00M
Total revenue 40840.00M 37520.00M 36277.00M 35409.00M 33530.00M
Total operating expenses 7404.00M 6153.00M 5962.00M 5746.00M 5392.00M
Cost of revenue 30115.00M 27209.00M 25961.00M 25061.00M 23696.00M
Total other income expense net -694.00000M -506.00000M -659.00000M -719.00000M -587.00000M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 2117.00M 2819.00M 2823.00M 3029.00M 3714.00M
Net income applicable to common shares 1372.00M 1818.00M 1707.00M 1883.00M 2027.00M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 76415.00M 71962.00M 66646.00M 67006.00M 56703.00M
Intangible assets 4399.00M 3831.00M 3736.00M 3869.00M 3130.00M
Earning assets - - - - -
Other current assets 845.00M 564.00M 527.00M 553.00M 478.00M
Total liab 44197.00M 42674.00M 40623.00M 40426.00M 31695.00M
Total stockholder equity 20415.00M 18998.00M 16949.00M 16778.00M 15411.00M
Deferred long term liab - 708.00M 681.00M 665.00M 640.00M
Other current liab 8552.00M 2424.00M 2170.00M 1943.00M 5906.00M
Common stock 563.00M 558.00M 557.00M 557.00M 556.00M
Capital stock 563.00M 558.00M 557.00M 557.00M 556.00M
Retained earnings - 14860.00M -1135.00000M -190.00000M -330.00000M
Other liab - 5229.00M 5267.00M 4740.00M 4380.00M
Good will 31444.00M 28943.00M 26599.00M 27737.00M 25713.00M
Other assets - 2442.00M 2220.00M 2231.00M 2210.00M
Cash 2175.00M 2610.00M 1837.00M 1654.00M 2709.00M
Cash and equivalents - - - - -
Total current liabilities 13658.00M 15062.00M 13216.00M 13884.00M 13275.00M
Current deferred revenue - 5827.00M 5560.00M 4528.00M 452.00M
Net debt 25588.00M 24545.00M 24076.00M 25604.00M 16425.00M
Short term debt 3036.00M 4772.00M 3670.00M 5508.00M 5094.00M
Short long term debt 2185.00M 3940.00M 2904.00M 4715.00M 4944.00M
Short long term debt total 27763.00M 27155.00M 25913.00M 27258.00M 19134.00M
Other stockholder equity 19852.00M 18440.00M 17527.00M 16411.00M 15185.00M
Property plant equipment 18841.00M 18583.00M 17603.00M 17266.00M 10366.00M
Total current assets 18279.00M 17461.00M 15772.00M 15264.00M 14790.00M
Long term investments - - - 1304.00M 1134.00M
Net tangible assets - -13068.00000M -12705.00000M -14163.00000M -12792.00000M
Short term investments 170.00M 136.00M 161.00M 133.00M 100.00M
Net receivables 10256.00M 9933.00M 9302.00M 9291.00M 8285.00M
Long term debt 18986.00M 27155.00M 16821.00M 16104.00M 14040.00M
Inventory 4833.00M 4218.00M 3945.00M 3633.00M 3218.00M
Accounts payable 2070.00M 2039.00M 1816.00M 1905.00M 1823.00M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 1499.00M 1012.00M 888.00M 861.00M 898.00M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 58136.00M 54501.00M 50874.00M 51742.00M 41913.00M
Capital lease obligations 6592.00M 6590.00M 6188.00M 6439.00M 150.00M
Long term debt total - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2607.00000M -7.00000M -33.00000M 26.00M 1093.00M
Change to liabilities 0.00000M -154.00000M 1819.00M 67.00M 223.00M
Total cashflows from investing activities -2607.00000M -2817.00000M -3011.00000M -4856.00000M -1464.00000M
Net borrowings - -398.00000M -1695.00000M 1019.00M -433.00000M
Total cash from financing activities -1604.00000M -1452.00000M -3117.00000M -484.00000M -1273.00000M
Change to operating activities - -320.00000M -252.00000M -368.00000M -345.00000M
Net income 2117.00M 2819.00M 2823.00M 3029.00M 3714.00M
Change in cash -15.00000M 927.00M 183.00M -1055.00000M 1073.00M
Begin period cash flow 2764.00M 1837.00M 1654.00M 2709.00M 1636.00M
End period cash flow 2749.00M 2764.00M 1837.00M 1654.00M 2709.00M
Total cash from operating activities 4198.00M 5078.00M 6549.00M 4263.00M 3742.00M
Issuance of capital stock 20.00M 38.00M 18.00M 49.00M 92.00M
Depreciation 2973.00M 2667.00M 2715.00M 2452.00M 1430.00M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid 890.00M 1068.00M 1060.00M 952.00M 904.00M
Change to inventory -472.00000M -105.00000M -527.00000M -315.00000M -279.00000M
Change to account receivables - 77.00M -13.00000M -593.00000M -544.00000M
Sale purchase of stock - 5571.00M -366.00000M -600.00000M -37.00000M
Other cashflows from financing activities 3466.00M -24.00000M 3595.00M 5763.00M 1577.00M
Change to netincome - 1127.00M 1294.00M 1110.00M 976.00M
Capital expenditures 1917.00M 2047.00M 2406.00M 2459.00M 3219.00M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -661.00000M -534.00000M 1028.00M -1182.00000M -691.00000M
Stock based compensation - - - - -
Other non cash items -231.00000M 126.00M -17.00000M -36.00000M -711.00000M
Free cash flow 2281.00M 3031.00M 4143.00M 1804.00M 523.00M

Peer Comparison

Sector: Healthcare Industry: Medical Care Facilities

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FSNUY
Fresenius SE & Co KGaA ADR		 -0.16 1.50% 10.54 16.87 9.44 0.42 0.78 0.79 5.37
HCA
HCA Holdings Inc		 -12.61 3.75% 323.55 13.19 13.66 1.13 293.44 1.77 8.22
FSNUF
Fresenius SE & Co. KGaA		 - -% 41.01 16.76 9.62 0.42 0.79 0.78 5.31
JDHIY
JD Health International Inc		 - -% 3.81 62.50 35.97 0.30 2.32 0.16 3.90
JDHIF
JD Health International Inc		 - -% 3.12 57.75 32.68 0.29 2.11 0.16 3.90

Reports Covered

Stock Research & News

View All

Profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Fresenius SE & Co KGaA ADR

Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, Germany, 61352

Key Executives

Name Title Year Born
Mr. Michael Sen CEO, Pres & Chairman of Management Board - Fresenius Management SE 1968
Dr. Francesco De Meo Member of Management Board - Fresenius Management SE 1963
Dr. Ernst Wastler Member of Management Board - Fresenius Management SE 1958
Dr. Sebastian Biedenkopf Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board 1964
Ms. Sara Hennicken CFO & Member of the Management Board - Fresenius Management SE 1980
Ms. Helen Giza Member of the Management Board - Fresenius Management SE 1968
Mr. Markus Georgi Sr. VP of Investor Relations NA
Matthias Link Sr. VP Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.